Organogenesis Stock Price, News & Analysis (NASDAQ:ORGO)

+0.86 (+14.70 %)
(As of 09/23/2019 03:49 AM ET)
Today's Range
Now: $6.71
50-Day Range
MA: $4.72
52-Week Range
Now: $6.71
Volume112,969 shs
Average Volume192,889 shs
Market Capitalization$634.77 million
P/E RatioN/A
Dividend YieldN/A
Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types. Its surgical and sports medicine products comprise ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical applications in targeted soft tissue repairs; and PuraPly AM for the surgical treatment of open wounds. The company's pipeline products include TransCyte for the treatment of second- and third-degree burns; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor for the treatment of chronic and acute wounds; Gintuit for the treatment of mucogingival conditions in adults; and PuraPly XT and PuraPly MZ for the treatment of chronic and acute wounds, as well as for surgical treatment of open wounds. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices. The company sells its products through direct sales representatives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ORGO



Sales & Book Value

Annual Sales$193.45 million
Book Value$0.52 per share



Market Cap$634.77 million
Next Earnings Date11/12/2019 (Confirmed)
OptionableNot Optionable

Receive ORGO News and Ratings via Email

Sign-up to receive the latest news and ratings for ORGO and its competitors with MarketBeat's FREE daily newsletter.

Organogenesis (NASDAQ:ORGO) Frequently Asked Questions

What is Organogenesis' stock symbol?

Organogenesis trades on the NASDAQ under the ticker symbol "ORGO."

How were Organogenesis' earnings last quarter?

Organogenesis Holdings Inc (NASDAQ:ORGO) issued its earnings results on Friday, August, 9th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.13) by $0.02. The firm had revenue of $64.95 million for the quarter, compared to analysts' expectations of $61 million. View Organogenesis' Earnings History.

When is Organogenesis' next earnings date?

Organogenesis is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Organogenesis.

How can I listen to Organogenesis' earnings call?

Organogenesis will be holding an earnings conference call on Tuesday, November 12th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Organogenesis issued on next quarter's earnings?

Organogenesis issued an update on its FY 2019 earnings guidance on Friday, August, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $250-262 million, compared to the consensus revenue estimate of $254.68 million.

What price target have analysts set for ORGO?

5 brokerages have issued twelve-month price objectives for Organogenesis' stock. Their forecasts range from $9.00 to $12.00. On average, they expect Organogenesis' stock price to reach $10.80 in the next year. This suggests a possible upside of 61.0% from the stock's current price. View Analyst Price Targets for Organogenesis.

What is the consensus analysts' recommendation for Organogenesis?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organogenesis in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Organogenesis.

What are Wall Street analysts saying about Organogenesis stock?

Here are some recent quotes from research analysts about Organogenesis stock:
  • 1. According to Zacks Investment Research, "Organogenesis is a leading regenerative medicine company focused on the development, manufacture and commercialization of solutions for the Advanced Wound Care and Surgical & Sports Medicine markets. " (9/20/2019)
  • 2. BTIG Research analysts commented, "We maintain our Buy rating and $12 PT on shares of ORGO following 1Q19 results. ORGO topped expectations across the board, with rev. of $57.1M beating BTIG/Consensus estimates of $50.6M/$52.6M bolstered by strength in PuraPly and Surgical & Sports Medicine (S&SM). FY19 guidance was raised by ~$2M (at the midpoint) ($248M-$259M to $249M-$262M) on the back of improved expectations in Surgical & Sports Medicine ($29.5M- $31.0M to $30M-$33M) and despite mfg. issues related to Affinity. We view guidance as a reflection of conservatism but confidence in underlying business fundamentals from increased rep growth, account growth, and further account penetration." (5/12/2019)

Has Organogenesis been receiving favorable news coverage?

News stories about ORGO stock have been trending somewhat negative on Monday, according to InfoTrie. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Organogenesis earned a news sentiment score of -1.3 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Organogenesis.

Are investors shorting Organogenesis?

Organogenesis saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 895,900 shares, an increase of 9.1% from the July 31st total of 821,500 shares. Based on an average daily trading volume, of 57,600 shares, the days-to-cover ratio is currently 15.6 days. Currently, 13.8% of the shares of the company are sold short. View Organogenesis' Current Options Chain.

Who are some of Organogenesis' key competitors?

What other stocks do shareholders of Organogenesis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Organogenesis investors own include BOK Financial (BOKF), RTI Surgical (RTIX), Polarityte (COOL), DavidsTea (DTEA), Aurora Cannabis (ACB), Aphria (APHA), Cleveland-Cliffs (CLF), Energy Transfer LP Unit (ET), Bed Bath & Beyond (BBBY) and Antares Pharma (ATRS).

Who are Organogenesis' key executives?

Organogenesis' management team includes the folowing people:
  • Mr. Gary S. Gillheeney Sr., Pres, CEO & Director (Age 64)
  • Mr. Timothy M. Cunningham, Chief Financial Officer (Age 57)
  • Mr. Patrick Bilbo, Chief Operating Officer (Age 57)
  • Ms. Lori H. Freedman, VP & Gen. Counsel (Age 52)
  • Angelyn Lowe, Director of Corp. Communications

Who are Organogenesis' major shareholders?

Organogenesis' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (0.61%), Vanguard Group Inc. (0.35%), Moors & Cabot Inc. (0.10%), Charles Schwab Investment Management Inc. (0.09%), Northern Trust Corp (0.04%) and Bank of New York Mellon Corp (0.03%). Company insiders that own Organogenesis stock include Alan A Ades, Arthur S Leibowitz, Avista Capital Managing Member and Michael W Katz. View Institutional Ownership Trends for Organogenesis.

Which major investors are buying Organogenesis stock?

ORGO stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Moors & Cabot Inc., Vanguard Group Inc., Bank of New York Mellon Corp, Citadel Advisors LLC, Northern Trust Corp and Charles Schwab Investment Management Inc.. Company insiders that have bought Organogenesis stock in the last two years include Alan A Ades, Arthur S Leibowitz, Avista Capital Managing Member and Michael W Katz. View Insider Buying and Selling for Organogenesis.

How do I buy shares of Organogenesis?

Shares of ORGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Organogenesis' stock price today?

One share of ORGO stock can currently be purchased for approximately $6.71.

How big of a company is Organogenesis?

Organogenesis has a market capitalization of $634.77 million and generates $193.45 million in revenue each year. Organogenesis employs 700 workers across the globe.View Additional Information About Organogenesis.

What is Organogenesis' official website?

The official website for Organogenesis is

How can I contact Organogenesis?

Organogenesis' mailing address is 85 Dan Road, Canton MA, 02021. The company can be reached via phone at 781-575-0775 or via email at [email protected]

MarketBeat Community Rating for Organogenesis (NASDAQ ORGO)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  24 (Vote Outperform)
Underperform Votes:  30 (Vote Underperform)
Total Votes:  54
MarketBeat's community ratings are surveys of what our community members think about Organogenesis and other stocks. Vote "Outperform" if you believe ORGO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ORGO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/23/2019 by Staff

Featured Article: Arbitrage

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel